OKUR · XBRL financial data

OnKure Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (OKUR's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	—	—	—	0	—
Research and development	28,169	37,705	56,613	43,795	48,260
General and administrative	11,649	16,143	26,440	10,591	14,690
Total operating expenses	39,818	53,848	83,053	54,386	62,950
Operating income (loss)	(39,818)	(53,848)	(83,053)	(54,386)	(62,950)
Other income (expense)	48	1,893	5,665	—	—
Income tax expense (benefit)	0	0	0	0	0
Net income (loss)	(39,770)	(51,955)	(77,388)	(52,673)	(59,517)
Earnings per share, basic USD per share	(2.19)	(2.12)	(2.52)	(15.28)	(4.40)
Earnings per share, diluted USD per share	(2.19)	(2.12)	(2.52)	(15.28)	(4.40)
Weighted average shares, basic thousands of shares	18,143	24,496	30,676	3,447	13,516
Weighted average shares, diluted thousands of shares	18,143	24,496	30,676	3,447	13,516

Fiscal years (OKUR's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	124,660	19,927	27,632	110,761	59,050
Short-term investments	23,010	81,246	75,331	—	—
Marketable securities	—	—	—	—	0
Prepaid and other current assets	6,064	5,180	3,659	2,242	1,789
Total current assets	153,734	106,353	106,622	113,003	60,839
Property and equipment, net	212	453	134	1,025	618
Right-of-use asset	—	1,292	599	770	387
Total assets	154,024	108,182	107,436	114,907	62,117
Accounts payable	2,022	1,893	8,717	2,968	1,433
Accrued liabilities	4,180	4,827	9,129	7,026	—
Total current liabilities	6,202	7,124	18,177	10,530	5,921
Lease liability, non-current	—	1,059	642	549	0
Total liabilities	6,813	8,212	18,826	11,079	5,933
Accumulated deficit	(84,728)	(136,683)	(218,474)	(154,724)	(214,241)
Total stockholders' equity	147,211	99,970	88,610	103,828	56,184
Total liabilities and equity	154,024	108,182	107,436	114,907	62,117
Common shares outstanding (cover page) thousands of shares	24,459	25,107	33,421	—	13,674

Fiscal years (OKUR's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(39,770)	(51,955)	(77,388)	(52,673)	(59,517)
Stock-based compensation	3,891	4,320	5,112	4,530	11,633
Depreciation and amortization	50	88	170	459	447
Net cash from operating activities	(37,983)	(47,362)	(63,682)	(51,117)	(51,828)
Purchases of property and equipment	198	346	221	52	46
Net cash from investing activities	(23,376)	(57,842)	10,522	15,873	(46)
Proceeds from issuing common stock	84,612	193	—	—	—
Share repurchases	—	—	4,403	—	—
Net cash from financing activities	132,406	471	60,865	116,129	163
Net change in cash	71,047	(104,733)	7,705	80,885	(51,711)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
OnKure Therapeutics	166,502	not reported	(10,354)*	40.5M	17.0 quarters	Q2 FY26 10-QJun 30, 2026
Champions Oncology	4,358	15,232	(492)	13.9M	8.0 quarters	Q1 FY27 10-QJul 31, 2026
Rockwell Medical	10,519	not reported	2,080*	4.0M	—	Q2 FY26 10-QJun 30, 2026
Outlook Therapeutics	11,242	not reported	(21,011)*	243.4M	0.5 quarters	Q3 FY26 10-QJun 30, 2026
Cumberland Pharmaceuticals	3,862	166	169*	15.0M	—	Q2 FY26 10-QJun 30, 2026
ProMIS Neurosciences	53,429	not reported	(10,385)*	9.0M	5.1 quarters	Q2 FY26 10-QJun 30, 2026
Tempest Therapeutics	779	not reported	(2,779)*	16.0M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
Palatin Technologies	7,492	301*	(2,690)*	1.8M	2.8 quarters	Q4 FY26 10-KJun 30, 2026
Scynexis	10,487	235	(14,885)*	9.9M	3.6 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.